P2Y receptors in health and disease.

Abstract

The purine- and pyrimidine-sensitive P2Y receptors belong to the large group of G-protein-coupled receptors that are the target of approximately one-third of the pharmaceutical drugs used in the clinic today. It is therefore not unexpected that the P2Y receptors could be useful targets for drug development. This chapter will discuss P2Y receptor-based therapies currently used, in development and possible future developments. The platelet inhibitors blocking the ADP-receptor P2Y(12) reduce myocardial infarction, stroke, and mortality in patients with cardiovascular disease. Clopidogrel (Plavix) was for many years the second most selling drug in the world. The improved P2Y(12) inhibitors prasugrel, ticagrelor, and elinogrel are now entering the clinic with even more pronounced protective effects. The UTP-activated P2Y(2) receptor stimulates ciliary movement and secretion from epithelial cells. Cystic fibrosis is a monogenetic disease where reduced chloride ion secretion results in a severe lung disease and early death. No specific treatment has been available, but the P2Y(2) agonist Denufosol has been shown to improve lung function and is expected to be introduced as treatment for cystic fibrosis soon. In preclinical studies, there are indications that P2Y receptors can be important for diabetes, osteoporosis, cardiovascular, and atherosclerotic disease. In conclusion, P2Y receptors are important for the health of humans for many diseases, and we can expect even more beneficial drugs targeting P2Y receptors in the future.

• Authors: David Erlinge
• Journal: Advances in pharmacology (San Diego, Calif.) (Adv Pharmacol) Vol. 61 Pg. 417-39 ( 2011) ISSN: 1557-8925 [Electronic] United States
• PMID: 21586366 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2011 Elsevier Inc. All rights reserved.

Chemical References

• Receptors, Purinergic P2Y
• Clopidogrel
• Ticlopidine
• Aspirin

Topics

• Animals
• Aspirin (pharmacology)
• Clopidogrel
• Disease
• Health
• Humans
• Platelet Activation (drug effects)
• Receptors, Purinergic P2Y (metabolism)
• Ticlopidine (analogs & derivatives, pharmacology)